See answer below
Novantrone is used in patients with both relapsing-remitting and secondary progressive ms.
It is a second line agent, after other agents failed to benefit the patient. It reduces the frequency of relapses and delays disease progression. Routine echocardiograms need to be obtained prior to each infusion. Infusions are administered every 3 months and limited to 8-9 infusions per lifetime.